Studies

Alleviation by NIAGEN of Persistent Chemotherapy-induced Peripheral Neuropathy in Cancer Survivors

Anesthesia Cancer Nephrology Kidney Disease Adult Subjects Female Subjects Male Subjects

The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds between 1 and 12 months earlier.